Molecular mechanism of allosteric modulation at GPCRs: Insight from a binding kinetics study at the human A1 adenosine receptor

British Journal of Pharmacology

Volumn 171, Issue 23, 2014, Pages 5295-5312

  Guo, Dong ^a   Venhorst, Suzanne N ^a   Massink, Arnault ^a   Van Veldhoven, Jacobus P D ^a   Vauquelin, Georges ^b   Ijzerman, Adriaan P ^a   Heitman, Laura H ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; LIGAND; PROTEIN BINDING;

ALLOSTERISM; ANIMAL; BINDING COMPETITION; CHEMICAL STRUCTURE; CHO CELL LINE; COMPUTER SIMULATION; CRICETULUS; HUMAN; KINETICS; METABOLISM;

ALLOSTERIC REGULATION; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; COMPUTER SIMULATION; CRICETULUS; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTOR, ADENOSINE A1;

EID: 84939982916     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12836     Document Type: Article

References (40)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. 1 receptors. J Biol Chem 287: 36944-36967.
3. 2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 47: 3707-3709.
4. 1 adenosine receptor coupling to G proteins. Biochim Biophys Acta 1265: 15-21.
5. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38: 939-949.
6. Christopoulos A, (2002). Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1: 198-210.
7. Christopoulos A, Kenakin T, (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374.
8. Copeland RA, (2005). Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal 46: 1-265.
9. Copeland RA, Pompliano DL, Meek TD, (2006). Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739.
10. 1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem Neurosci 4: 1026-1048.
11. De Amici M, Dallanoce C, Holzgrabe U, Trankle C, Mohr K, (2010). Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev 30: 463-549.
12. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE, (2011). International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63: 1-34.
13. Gao ZG, Jacobson KA, (2007). Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 12: 479-492.
14. Gao ZG, Jacobson KA, (2013). Allosteric modulation and functional selectivity of G protein-coupled receptors. Drug Discov Today Technol 10: e237-e243.
15. Gao ZG, Kim SK, IJzerman AP, Jacobson KA, (2005). Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem 5: 545-553.
16. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol 60: 1057-1063.
17. Göblyös A, IJzerman AP, (2011). Allosteric modulation of adenosine receptors. Biochim Biophys Acta 1808: 1309-1318.
18. Gregory KJ, Sexton PM, Christopoulos A, (2007). Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol 5: 157-167.
19. Guo D, Hillger JM, IJzerman AP, Heitman LH, (2014). Drug-target residence time-a case for G protein-coupled receptors. Med Res Rev 34: 856-892.
20. 2A receptor agonists is positively correlated to their receptor residence time. Br J Pharmacol 166: 1846-1859.
21. Guo D, van Dorp EJ, Mulder-Krieger T, van Veldhoven JP, Brussee J, IJzerman AP, et al. (2013). Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen 18: 309-320.
22. Keov P, Sexton PM, Christopoulos A, (2011). Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60: 24-35.
23. Kostenis E, Mohr K, (1996). Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17: 280-283.
24. Lane JR, Sexton PM, Christopoulos A, (2013). Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci 34: 59-66.
25. Lazareno S, Birdsall NJM, (1995). Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G-protein-coupled receptors-interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48: 362-378.
26. 1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 337: 687-689.
27. May LT, Self TJ, Briddon SJ, Hill SJ, (2010). The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells. Mol Pharmacol 78: 511-523.
28. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, et al. (2012). Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 55: 1445-1464.
29. Motulsky HJ, Mahan LC, (1984). The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25: 1-9.
30. 1 adenosine receptors and their ligands: overview and recent developments. Farmaco 56: 77-80.
31. Müller CE, Schiedel AC, Baqi Y, (2012). Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. Pharmacol Ther 135: 292-315.
32. 1 receptor. J Med Chem 53: 3028-3037.
33. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
34. 1 adenosine receptor. J Med Chem 51: 5875-5879.
35. 2 muscarinic receptor. Mol Pharmacol 72: 291-302.
36. Vauquelin G, (2013). Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time. Naunyn Schmiedebergs Arch Pharmacol 386: 949-962.
37. Vauquelin G, Bricca G, Van Liefde I, (2013). Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands. Fundam Clin Pharmacol 1-14. doi: 10.1111/fcp.12052
38. Vauquelin G, Charlton SJ, (2013). Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol 168: 1771-1785.
39. Wang CI, Lewis RJ, (2013). Emerging opportunities for allosteric modulation of G-protein coupled receptors. Biochem Pharmacol 85: 153-162.
40. Zhang R, Monsma F, (2010). Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs. Expert Opin Drug Discov 5: 1023-1029.